Pulmonary Fibrosis

HomePatientsLung Disease Week at the ATS2014 ▶ Pulmonary Fibrosis
Pulmonary Fibrosis Week

Pulmonary Fibrosis Week

Welcome Message

Pulmonary Fibrosis Week was designed to raise awareness about disorders causing pulmonary fibrosis.  These disorders, characterized by excessive deposition of scar tissue in lung, are difficult to treat and are often progressive leading to poor lung function and sometimes death.  Pulmonary fibrosis can be triggered or worsened by environmental / occupational exposures (e.g., asbestos), tobacco smoke, infection, or drugs.  However, in some cases, the cause is unknown as is the case for Idiopathic Pulmonary Fibrosis (IPF), the most common of the idiopathic interstitial pneumonias.  IPF affects close to 200,000 people in the U.S. and many more worldwide and carries a poor prognosis with 50% mortality in 3 years.  Currently, there are no FDA-approved drugs known to improve survival in IPF, but many clinical trials are underway and some strategies seem promising.  The ATS has been at the forefront of efforts designed to curtail the effects of pulmonary fibrosis.  For example, the ATS houses clinical experts and scientists who study IPF and who are leading the way towards new discoveries in this field.  By providing a forum for the dissemination of information through conferences and consensus statements, the ATS has raised awareness about the condition, while promoting better care for these patients.  In partnership with private foundations, industry and government, the ATS funds research in pulmonary fibrosis that we hope will unveil potential new targets for intervention.  Through these and related efforts, the ATS is expected to usher in a new era where safe and effective treatments and perhaps preventive interventions are available for patients with pulmonary fibrosis.

Jesse Roman Rodriguez, MD

Jesse Roman, MD         
Immediate Past Chair, Respiratory
& Molecular Biology Assembly
Member, ATS Board of Directors

Teresa Barnes

Teresa Barnes
Immediate Past Chair, ATS
Public Advisory Roundtable


The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of Pulmonary Fibrosis issues; and works to improve awareness of Pulmonary Fibrosis in the medical community as well as the general public. The CPF’s nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 17,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis.